#Canada #Toronto #Xtalks #Cognitive Data #Sleep-Wakefulness

Enhancing Drug Evaluation through Cognitive Data

Xtalks is excited to announce an upcoming free webinar titled "Leverage Cognitive Data to Improve Sleep-Wakefulness Drug Evaluation", scheduled for April 22, 2026. This essential session aims to highlight the importance of cognitive assessments in clinical trials for sleep medicine, addressing the increasing need for robust data in this field.

Disruptions in natural sleep/wake cycles can arise due to various factors, including diseases, disorders affecting the central nervous system (CNS), or even the medications designed to treat these conditions. These disruptions often lead to a significant degree of disability, increased morbidity, and in some cases, heightened mortality risks. Thus, understanding the cognitive symptoms that accompany difficulty in sleeping or remaining awake has become a vital area of research.

In evaluating sleep medicines, clinical development teams frequently encounter challenges due to inconsistent terminology and limited alignment between subjective reports and objective cognitive data. This webinar intends to tackle those issues by illuminating how cognitive functions can be systematically measured to enhance clarity and decision-making in drug evaluation programs.

The session will feature Professor Paul Maruff, a leading authority in cognitive data analysis and the Chief Innovation Officer at Cogstate. He will discuss the significance of measuring cognition in sleep medicine trials, sharing insights on how patients with disrupted sleep-wake cycles can exhibit cognitive deficits. Paul's approach centers on utilizing data from various groups, including those experiencing sleep restrictions and healthy adults administered sedative medications, to quantify cognitive changes accurately.

Throughout the webinar, important concepts will be covered, including:

• - The integration of subjective reports with standardized neuropsychological tests to generate reliable data.
• - Clarifying ambiguous terms like fatigue, drowsiness, sleepiness, and sedation, which often overlap, leading to confusion in trial outcomes.
• - The framework leveraging cognitive data to enhance endpoint selection, safety monitoring, and efficacy evaluations at different stages of development.

By participating in this valuable session, attendees will gain insights into how cognitive measurement can guide safety and efficacy decisions in the development of sleep medicines. This information is crucial for aligning the objectives of clinical trials with patient outcomes, ensuring that drug evaluations are both scientific and grounded in the realities of patient experience.

Don’t miss the opportunity to learn from experts in the field and ensure that your understanding of cognitive data’s role in drug development is current and comprehensive. Join us on April 22, 2026, at 4 PM EDT (1 PM PDT) for this impactful discussion. For more information and to register, visit the Xtalks website today!

ABOUT XTALKS

Xtalks specializes in empowering professionals within the life sciences sector, including pharma, biotech, and healthcare, by providing timely news, webinars, podcasts, and articles tailored to support informed decision-making. Thousands of professionals rely on Xtalks each year for current industry insights and collaborative opportunities. Connect with our life science community to stay informed about the latest trends and research.

To learn more about Xtalks, visit www.xtalks.com.

For inquiries regarding hosting webinars or collaborative opportunities, please contact Vera Kovacevic at +1 (416) 977-6555 x371 or email [email protected].